A Progressive Resistance Training Program in Patients With Haemophilia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-24

Study Completion Date

2018-06-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the clinical impact of a progressive resistance training program in adults patients with haemophilia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Could Physical Activity Help to Counteract the Blood Haemophilia Disturbance? A Pilot Study.

NCT02851082

Hemophilia A

COMPLETED NA

Transcultural Multidisciplinary Evaluation of Patients With Hemophili

NCT02199639

Patients With Haemophilia

UNKNOWN

Multidisciplinary Evaluation of Patients With Hemophilia

NCT02198430

Haemophilia

COMPLETED

He-move-philia, Lifestyle Intervention for Patients With Hemophilia

NCT05608863

Hemophilia

ACTIVE_NOT_RECRUITING NA

An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia

NCT02199717

Hemophilia A Hemophilia B Factor VIII Deficiency +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The training program aims improving muscular strength and endurance in the relevant muscles and joints (knee, elbow, ankle, shoulder and hip) in order to improve the quality of life in the patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Haemophilia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Training group

Each subject will participate in 2 sessions each week during 8 weeks, with 3 days of difference (rest) between the sessions.

Group Type EXPERIMENTAL

Progressive resistance training

Intervention Type OTHER

Progressive resistance training program

Control group

Usual daily activities

Group Type PLACEBO_COMPARATOR

Normal daily activities

Intervention Type OTHER

Usual daily activities

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Progressive resistance training

Progressive resistance training program

Intervention Type OTHER

Normal daily activities

Usual daily activities

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of haemophilia A or B
* willingness to exercise twice a week during the training program and to complete the pre- and post-program evaluations
* approval by their hematologist to participate in the exercise program
* age between 18 and 60 years
* informed consent signed.

Exclusion Criteria

* the inability to attend exercise sessions at least twice a week for 6 consecutive weeks
* non adherence to instruction on proper exercise technique
* surgical procedures performed 6 weeks prior to or during the exercise program
* participation in any other form of exercise, including rehabilitation, during the study; (5) changes in medication during the study
* a major bleeding episode that posed a risk or prevented exercise
* History of FVIII inhibitor (titer ≥ 0.6 BU \[Bethesda unit\]) or detectable FVIII inhibitors at screening (titer ≥ 0.4 BU)
* Another haemostatic defect
* Need for major surgery
* Withdrawal of informed consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No